These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25907439)

  • 1. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
    van Haaften C; Boot A; Corver WE; van Eendenburg JD; Trimbos BJ; van Wezel T
    J Exp Clin Cancer Res; 2015 Apr; 34(1):38. PubMed ID: 25907439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
    Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
    Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
    [No Abstract]   [Full Text] [Related]  

  • 3. Potent cytotoxic effects of Calomeria amaranthoides on ovarian cancers.
    van Haaften C; Duke CC; Weerheim AM; Smit NP; van Haard PM; Darroudi F; Trimbos BJ
    J Exp Clin Cancer Res; 2011 Mar; 30(1):29. PubMed ID: 21401934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
    van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
    Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells.
    Takai N; Ueda T; Nishida M; Nasu K; Narahara H
    Int J Mol Med; 2010 Jan; 25(1):97-103. PubMed ID: 19956907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.
    Moxley KM; Chengedza S; Benbrook DM
    Gynecol Oncol; 2009 Dec; 115(3):438-42. PubMed ID: 19804900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
    Dasari VR; Carey DJ; Gogoi R
    BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
    Ayyagari VN; Diaz-Sylvester PL; Hsieh TJ; Brard L
    PLoS One; 2017; 12(9):e0185111. PubMed ID: 28931042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
    Çoban HŞ; Çil N; Önder E; Abban Mete G
    Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
    Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
    Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    Ayyagari VN; Hsieh TJ; Diaz-Sylvester PL; Brard L
    BMC Cancer; 2017 Jan; 17(1):49. PubMed ID: 28086831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase.
    Li X; Wang G; Zhao J; Ding H; Cunningham C; Chen F; Flynn DC; Reed E; Li QQ
    Cell Mol Life Sci; 2005 Apr; 62(7-8):894-904. PubMed ID: 15868412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.